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ABSTRACT 
Background: Streptokinase (SK) is most widely used for treatment of myocardial infarction, however, it is the most 
expensive thrombolytic agent. A major drawback to SK use is the widespread presence of anti–streptokinase antibodies 
(Abs).  These Abs cause allergic reactions and neutralize streptokinase therapeutic effects.  
Materials and methods: To produce an engineered variant of streptokinase being functional and less antigenic than the 
native molecule, we cloned and expressed streptokinase mutant gene lacking the C – terminal 42 amino acids. 
Recombinant protein was confirmed by western blot analysis with anti T7 monoclonal antibodies.  
Results: pGEMEX-1 expression vector contains T7 gene 10 protein as fusion protein immediately down stream of T7 
promoter and before multiple cloning site, streptokinase mutant gene was cloned after fusion protein.  
Conclusion: We cloned and expressed mutant streptokinase gene, lacking the C-terminal 42 amino acids. If mut-C42 
activity was less affected by neutralizing antibodies compared with native streptokinase, this engineered variant could be 
a preferred alternative to native streptokinase for thrombolytic therapy.  
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1A blood clot developed in circulatory system 
can cause vascular blockage leading to death. In 
mammalian, the enzyme responsible for 
fibrinolysis is plasmin. The active plasmin is 
produced from the inactive plasminogen which is 
mediated by the various plasminogen activators. 
Streptokinase, a protein consist of 414 amino acids 
residues produced by β hemolytic streptococci has 
been used in the therapy of acute myocardial 
infarction (AMI) for its strong activity in 
dissolving fibrin. This protein is a plasminogen 
activator (1). Shortly after discovering the 
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fibrinolytic effects of streptokinase, its 
immunogenicity was reported (2). Antibodies to 
streptokinase are found in most individuals due to 
the high frequency of streptococcal infections (3). 
Moreover, when patient receives streptokinase, 
antibody titers raise.  These neutralizing antibodies 
reduce the efficiency of thrombolytic therapy and 
may cause a range of allergic reactions (4-6).   
Previous reports have identified 5 antigenic 
regions in SK localized to fragments spanning 
amino acid residues 1-13, 14-127, 1-253, 120-353, 
353-414 (7,8). Some studies are performed based 
on evidences about the presence of an 
immunodominant epitope in the C-terminal region 
of native molecule (9,10). A deletion mutant (mut-
C42), lacking the C-terminal 42 amino acids, 
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showed to be less recognized and less neutralized 
by anti-streptokinase antibodies from patients sera 
respect to the native protein  (11,12). 
Comparative clinical trials in the treatment of 
acute myocardial infarction suggested that 
streptokinase is a cost effective and useful 
thrombolytic drug (1). Hence, several studies have 
been conducted focusing on production and 
improvement of streptokinase (13-16). 
To compare the reactivity of anti streptokinase 
antibodies to mut-C42 and native streptokinase in 
Iranian patients’ sera, we cloned and expressed the 
streptokinase mutant gene lacking the C–terminal 
42 amino acids in pGEMEX-1 expression vector 
for further studies.  
 
MATERIALS and METHODS 
We used cloned streptokinase mutant gene 
which have been cloned in pGEMEX-1 expression 
vector at SacI and BamHI restriction sites during 
another our study (16). Competent cells were 
prepared by E.coli XL1-Blue based on Hnanahan 
method (17) and transformed with recombinant 
pGEMEX-1 plasmid. A bacterial colony contained 
recombinant plasmid was mass cultured in LB 
medium and plasmid was extracted (18). 
Streptokinase mutant gene (1116bp) was amplified 
by PCR (19). PCR mix contained 1x PCR buffer, 
0.1mM dNTP, 1.5mM MgCl2, 100ng recombinant 
pGEMEX-1 plasmid DNA, 40pmol of each 
forward and reverse primers and 1.25unit Taq 
DNA polymerase in 30µl volume.   
PCR reaction was achieved by flowing 
parameters: denaturation at 94ºC for 30 seconds, 
annealing at 60ºC for 1 minute and extension at 
72ºC for 40 seconds, repeated 30 cycles. PCR 
product was electrophoresed on 1% low melting 
point agarose gel and DNA band was sliced under 
long wave UV and recovered by DNA extraction 
kit (Fermentas Cat. No k0513).  PCR product was 
sequenced and deposited to Gene Bank.  
Gene expression from the pGEMEX-1 Vectors 
is based on the T7 expression system which uses a 
convenient vector/host combination for high-level 
expression of cloned genes in vivo. Sequences 
cloned into the pGEMEX1- Vectors are expressed 
as T7 gene 10 fusion proteins in JM109 (DE3) or 
BL21 (DE3) pLysS host strains containing an 
inducible gene for T7 RNA polymerase. JM109 
(DE3) is a specially constructed host strain that 
contains an IPTG inducible gene for T7 RNA 
polymerase. PGEMEX -1 plasmid was transformed 
into the bacterial strain JM109 (DE3) (Promega, 
technical bulletin no.2, www.promega.com). A 
colony contained recombinant plasmid was 
cultured on shacking incubator for overnight at 
37°C in 50ml LB medium containing 100µg/ml 
ampicillin. The next day, 1–2ml of culture was 
removed and inoculated into 50ml fresh LB 
medium containing 100µg/ml ampicillin. The 
culture was grown up to an A600 of 0.6. Then 
induced with 1mM IPTG (isopropyl betathio 
galactopyranoside) and incubated the culture for an 
additional 3–5 hours. For sampling, we removed 
100–200µl of the culture and cells were 
precipitated by micro centrifuge.  The bacterial 
pellet was resuspended in 100µl of resuspension 
buffer (100 mM Tris–HCl pH 8, 20% glycerol, 4% 
SDS, 2% β-mercaptoethanol, 0.2% bromophenol 
blue) to solubilize the fusion protein. Sample was 
centrifuged to pellet the insoluble fusion protein. 
The sample in parallel with uninduced control 
culture was analyzed by SDS-PAGE. The gel was 
stained with Coomassie brilliant blue R-250 (20). 
For western blot analysis, SDS-PAGE gel was 
transferred to nitrocellulose membrane and 
analyzed by western blot. Briefly, nitrocellulose 
sheet was immersed in 3% bovine serum albumin 
in Tris buffered saline, 0.1% Tween 20 at room 
temperature for 1 hour to block excess protein-
binding sites. The nitrocellulose sheet was reacted 
with T7 mono clonal antibody as primary antibody 
at room temperature and washed in TBS buffer. 
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Immune reactions were identified by secondary 
antibody (anti sheep anti mouse IgG conjugated to 
horseradish peroxidase). Color development 
(antigen–antibody reaction) was observed by 




Expression vector: pGEMEX-1 expression 
vector contain T7 gene 10 protein (figure 1) as 
fusion protein immediately down stream of T7 
promoter and before multiple cloning site, 
streptokinase mutant gene was cloned after fusion 
protein (figure 2). Expressed gene will be fused 
with T7 gene 10 protein and will be detected by T7 


























PCR reaction: Figure 3 shows 1% agarose gel 
electrophoresis of 1116 bp as PCR product of 
streptokinase mutant gene. PCR product was 
sequenced and deposited to Gene Bank at 













SDS-PAGE: Collected bacterial samples were 
lysed by lysis buffer and subjected to 
electrophoresis on 10% SDS-PAGE and stained by 
coomassie brilliant blue G250. Figure 4 shows the 
stained SDS-PAGE and expressed recombinant 
protein is shown in lane 4 (74 KDa:  42 KDa for 
streptokinase and 32 KDa for T7 gene 10 protein) 


















Figure 1. Map of pGEMEX-1 expression vector
          Figure 2. Multiple cloning site of pGEMEX-1 
          expression vector 
 
Figure 3. 1% agarose gel electrophoresis. Lane 1: 
Streptokinase mutant PCR product. Lane 2:100bp 
DNA ladder marker. 
 
Figure 4. 10% SDS-PAGE. Lane 1: Lysate cells of 
JM109. Lane 2: Lysate bacterial cell containing 
pGEMEX-1. Lane 3: Lysate of JM109 cells 
containing rpGEMEX-1 before induction. Lane 4:  
Lysate of JM109 cells containing rpGEMEX-1 5 
hours after induction. Lane 5: Protein size marker. 
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Western blotting: SDS-PAGE gel was 
transferred on nitrocellulose membrane and 
detected by colorimetric method (western blot 
serological test).  
 
DISCUSSION 
Several different M serotypes of group A 
streptococci can cause human plasma to clot in 
nutrient-poor media (23). A blood clot developed 
in circulatory system can cause vascular blockage 
leading to death and circulatory plasmin enzyme is 
responsible for fibrinolysis in mammalian. The 
active plasmin is produced from the inactive 
plasminogen which is mediated by the various 
plasminogen activators. Streptokinase is a 
plasminogen activator and has been used in the 
therapy of acute myocardial infarction for its fibrin 
dissolving activity (1). Plasminogen activators are 
agents that are currently applied as thrombolytic 
therapy to achieve rapid vascular reperfusion (24).  
Previous reports have shown 5 antigenic regions in 
streptokinase, mapped with soluble recombinant 
streptokinase fragments and anti-SK Abs from 
human sera from patients treated with 
streptokinase. These regions comprise amino acids 
1-13, 1-253, 120-352 (containing two distinct, non 
overlapping epitopes) and 353-414. The data 
indicated that all patients raise antibodies against 
two major discrete regions, 1-253, 120-352. Two 
other epitopes in streptokinase constructed by 
amino acids 1-13 and 353-414 were not antigenic 
in all humans tested in this study (8). Torrens et al 
mapped the antigenic regions (linear epitopes) 
located on streptokinase, using human total sera 
from patients treated with Heberkinase. As a result 
they showed that C-terminal region 380-490 among 
other fragments is notably immunodominant (9). 
Ojalvo et al reported that 30% of 1008 normal 
donors recognized a synthetic peptide resembling 
amino acids 373-414 from streptokinase C-terminal 
region (10). Then immunoreactivity of the 
synthetic 42–residue peptide with sera from AMI 
patients before and after Heberkinase therapy was 
tested. This peptide was recognized by 39% of 
patients before therapy and as it was expected, 
recognition increased to 64 % after therapy. This is 
evidence about immune response towards C-
terminal region of streptokinase (9,12). These 
studies were complemented by performing a 
competition experiment in which both native and 
mutant (lacking C-terminal 42 amino acids) 
proteins were tested in a neutralizing activity assay 
using patient’s sera. For most of the individuals, 
mut-C42 neutralizing activity titer (NAT) 
significantly decreased with respect to native SK-
NAT and mut–C42 was significantly less 
recognized by pre-existing anti-streptokinase 
antibodies than the native streptokinase (9). Then, 
the immune response to mut-C42 and native 
molecule was tested in animals. 14 monkeys were 
subjected with native molecule and mut-C42. All 
monkeys developed anti-streptokinase antibodies, 
but in the case where treatment induced antibodies 
directed against the C-terminus of SK, neutralizing 
activity against the native protein was significantly 
higher than that developed against mutant-C42 
(11). This data indicate that the immunodominant 
epitope in the C-terminal of native streptokinase 
can be eliminated without loss of specific activity.  
We cloned and expressed mutant streptokinase 
gene, lacking the C-terminal 42 amino acids. If 
mut-C42 activity was less affected by neutralizing 
antibodies compared with native streptokinase, this 
engineered variant could be a preferred alternative 
to native streptokinase for thrombolytic therapy.  
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